A Phase 2 interventional study of Duvelisib in Hematologic Malignancy, sponsored by SecuraBio. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-11.
Sponsored by SecuraBio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.
Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 483rd largest by enrollment of the 658 interventional ones that give a count, is one of 45 that started in 2016, is one of 194 in phase 2, and was the 351st registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Orum Therapeutics USA, Inc. · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
821 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 276 · Phase 2 280 · Phase 3 43 · Phase 4 9
First in 1989; this study’s year is marked. 45 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 40 across the 658 interventional studies, 150 across the 157 observational. Of the 497 that completed or were terminated, 208 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 821 have an industry lead sponsor. The 10 most frequent:
SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
SecuraBio has 2 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
90 of the studies in Hematologic Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT04188418Phase 3M.D. Anderson Cancer CenterFentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients | 2027-08-31 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT02203903Catherine BollardMulti-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | 2026-11-30 |
Add all 90 to your calendar (.ics) → With an account.
Among the 821 studies in Hematologic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a long-term, continued treatment study that evaluated the long-term safety, clinical activity, and overall survival (OS) of duvelisib in individuals with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.
Study IPI-145-23 was an international, multicenter, open-label, single-arm, Phase 2 study designed to evaluate the long-term safety, clinical activity, and overall survival data of duvelisib in individuals with hematologic malignancies. Only individuals who have participated in a previous duvelisib study that were approved by the sponsor were allowed to enroll in the study.
Participants in active treatment and participants in survival follow-up were allowed to rollover to this study. For participants on active treatment, participants continued the same dose from their previous duvelisib study administered twice daily for 28-day continuous cycles until disease progression or unacceptable toxicity and then followed in a survival follow-up period. For participants in survival follow-up, participants continued to be followed-up for survival in this study for the duration as outlined in their previous duvelisib study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have participated in a previous study of duvelisib, and:
Exclusion Criteria:
Participants received the same dose from their previous duvelisib study. All doses were taken twice daily. Two dose reductions were allowed per participant, but doses were not less than 10 milligrams (mg). Participants received duvelisib until disease progression or unacceptable toxicity.
Drug: Duvelisib
Administered as oral capsules
Also known as: IPI-145, VS-0145, COPIKTRA
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Up to 45 months
Best Overall Response (BOR) to Duvelisib as Assessed by the Investigator
There were no formal secondary endpoints planned and captured data was based on disease response assessment and overall survival (OS) as defined in the participant's previous study. BOR was defined as the best time point response that a participant achieves during the study, with the response ranked according to the following order (from best to worst): complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR), stable disease (SD).
Time frame: Up to 45 months
Overall Survival (OS)
No formal secondary endpoints were planned for this study. OS was monitored in participants who continued to receive duvelisib treatment and/or in the long-term survival follow-up period in a previous duvelisib study and the number of participants alive at end of study were reported. Participants being followed for OS were contacted by the study site approximately every 6 months to collect survival status and data pertaining to any other alternative antineoplastic therapy.
Time frame: Up to 45 months
A total of 19 participants were enrolled in the current study from 3 previous studies: IPI-145-01(NCT01549106), IPI-145-02 (NCT01476657), and IPI-145-08 (NCT02204982).
| Milestone | Duvelisib |
|---|---|
| Started | 19 |
| Received at least 1 dose of study drug | 19 |
| Completed | 9 |
| Not completed | 10 |
| Withdrew: Death | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Completed follow-up | 3 |
| Withdrew: Withdrawal by subject | 1 |
A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Participants | Duvelisib |
|---|---|
| Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 17 |
There were no formal secondary endpoints planned and captured data was based on disease response assessment and overall survival (OS) as defined in the participant's previous study. BOR was defined as the best time point response that a participant achieves during the study, with the response ranked according to the following order (from best to worst): complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR), stable disease (SD).
| Participants | Duvelisib |
|---|---|
| CR/CRi | 9 |
| PR | 5 |
| SD | 1 |
| Response not evaluable | 1 |
No formal secondary endpoints were planned for this study. OS was monitored in participants who continued to receive duvelisib treatment and/or in the long-term survival follow-up period in a previous duvelisib study and the number of participants alive at end of study were reported. Participants being followed for OS were contacted by the study site approximately every 6 months to collect survival status and data pertaining to any other alternative antineoplastic therapy.
| Participants | Duvelisib |
|---|---|
| Overall Survival (OS) | 14 |
Collected over Up to 45 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Duvelisib | 5/19 (26.3%) | 5/19 (26.3%) | 16/19 (84.2%) |
| Event | Duvelisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 1/19 |
| EnteritisGastrointestinal disorders | 1/19 |
| FatigueGeneral disorders | 1/19 |
| PyrexiaGeneral disorders | 1/19 |
| Pneumonia cytomegaloviralInfections and infestations | 1/19 |
| Pneumonia viralInfections and infestations | 1/19 |
| Pseudomonal sepsisInfections and infestations | 1/19 |
| FallInjury, poisoning and procedural complications | 1/19 |
| HypokalaemiaMetabolism and nutrition disorders | 1/19 |
| HyponatraemiaMetabolism and nutrition disorders | 1/19 |
| Event | Duvelisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 5/19 |
| AnaemiaBlood and lymphatic system disorders | 4/19 |
| FatigueGeneral disorders | 4/19 |
| Upper respiratory tract infectionInfections and infestations | 4/19 |
| Abdominal painGastrointestinal disorders | 3/19 |
| HypokalaemiaMetabolism and nutrition disorders | 3/19 |
| NeutropeniaBlood and lymphatic system disorders | 2/19 |
| Oedema peripheralGeneral disorders | 2/19 |
| PyrexiaGeneral disorders | 2/19 |
| InfluenzaInfections and infestations | 2/19 |
All Treated Analysis Set included all participants who received at least one dose of duvelisib.
| Age, Continuous(years) | Duvelisib |
|---|---|
| Mean | 63.8 ± 10.84 |
| Sex: Female, Male(Participants) | Duvelisib |
|---|---|
| Female | 11 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Duvelisib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Duvelisib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 18 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in May 2020, 49 months.
Results were first posted in Feb 2023, 2 years 9 months after primary completion.
Of 136 phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 94. This study's 49 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvelisib